In the absence of a submission from the holder of the marketing authorisation, decitabine (Dacogen®) cannot be endorsed for use within NHS Wales for the treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukaemia, according to the World Health Organisation classification, who are not candidates for standard induction chemotherapy.